This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cooper, M. S. Articles by Stewart, P. M. Search for Related Content PubMed PubMed Citation Articles by Cooper, M. S. Articles by Stewart, P. M. Related Collections Adrenal and Hypertension Metabolism

11β-Hydroxysteroid Dehydrogenase Type 1 and Its Role in the Hypothalamus-Pituitary-Adrenal Axis, Metabolic Syndrome, and Inflammation

Centre for Endocrinology, Diabetes, and Metabolism, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, United Kingdom B15 2TT

Address all correspondence and requests for reprints to: Professor Paul M. Stewart, F.R.C.P., F.Med.Sci. E-mail: p.m.stewart{at}bham.ac.uk.

Context: 11β-Hydroxysteroid dehydrogenase (11β-HSD) enzymes are now appreciated to be important regulators of hormone action at a tissue level. 11β-HSD1 is widely expressed and increases glucocorticoid action through its unique ability to convert inactive glucocorticoids (cortisone in man, 11-dehydrocorticosterone in rodents) to their active forms (cortisol and corticosterone, respectively). The enzyme has roles in the normal hypothalamus-pituitary-adrenal (HPA) axis, has been implicated in metabolic syndrome, and may modulate various aspects of the immune response.

Evidence Acquisition: A review of published, peer-reviewed medical literature (1990 to June 2009) on the physiology and pathophysiology of 11β-HSD1 was performed with an emphasis on HPA axis consequences, the metabolic syndrome, and the inflammatory response.

Evidence Synthesis: Studies of patients with genetic defects in 11β-HSD1 action show abnormal HPA axis responses with hyperandrogenism being a major consequence. The mechanisms underlying these abnormalities have been explored in mouse models with targeted deletion of components of the 11β-HSD1 system. A range of experimental studies emphasize the role of 11β-HSD1 in the metabolic syndrome and the potential for treatment with chemical inhibitors. An emerging area is the role of 11β-HSD1 in the inflammatory response.

Conclusions: 11β-HSD1 activity is an important component of the HPA axis and contributes to the metabolic syndrome and the normal immune response. Ongoing clinical observations and the development of selective inhibitors will further clarify the role of 11β-HSD1 in these areas.

This article has been cited by other articles:

				K. Raza, R. Hardy, and M. S. Cooper The 11{beta}-hydroxysteroid dehydrogenase enzymes--arbiters of the effects of glucocorticoids in synovium and bone Rheumatology, July 15, 2010; (2010) keq212v1. [Abstract] [Full Text] [PDF]